UBS Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

UBS Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,000	Closed	-$62.4K	–	10492
2025 Q4	$62.4K	Hold	8,000	–	–	﹤0.01%	7120
2025 Q3	$60.7K	Hold	8,000	–	–	﹤0.01%	7427
2025 Q2	$71.7K	Hold	8,000	–	–	﹤0.01%	7495
2025 Q1	$60K	Hold	8,000	–	–	﹤0.01%	7440
2024 Q4	$60.2K	Hold	8,000	–	–	﹤0.01%	7182
2024 Q3	$60.8K	Hold	8,000	–	–	﹤0.01%	6689
2024 Q2	$49.4K	Buy	+8,000	New	+$44.1K	﹤0.01%	6697
2023 Q3	–	Sell	-26,800	Closed	-$189K	–	9456
2023 Q2	$189K	Hold	26,800	–	–	﹤0.01%	5519
2023 Q1	$224K	Hold	26,800	–	–	﹤0.01%	5300
2022 Q4	$308K	Hold	26,800	–	–	﹤0.01%	5101
2022 Q3	$338K	Buy	+26,800	New	+$345K	﹤0.01%	4678

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

UBS Group's BCRX Position: Q2 2026 in Review

UBS Group increased its BioCryst Pharmaceuticals (BCRX) stake by 2.7% in Q2 2026, buying an estimated $1.21M and bringing the position to 5,078,280 shares worth $50.8M. The position accounts for 0.01% of the portfolio, ranked #1729.

UBS Group first reported a position in BCRX in Q4 2014 and has held it in 47 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

UBS Group held 5,078,280 shares of BioCryst Pharmaceuticals worth $50.8M as of Q2 2026.
UBS Group bought 134,286 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.21M.
BioCryst Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1729 holding.
UBS Group first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.